Antitumor Activity of MDV3100 in a Phase 1-2 Study of Castration-Resistant Prostate Cancer H. I. Scher, T. Beer, C. Higano, M. Taplin, E. Efstathiou, A.
Immunotherapy for Prostate Cancer: Are we on the right target?
Antitumor Activity of MDV3100 in a Phase 1-2 Study of Castration-Resistant Prostate Cancer
Treatment of Advanced Prostate Cancer: The Changing Landscape Wm. Kevin Kelly, DO Professor, Medical Oncology and Urology Director, Division of Solid Tumor.
